natgillin/translations-raw huggingface dataset:
500 mikrogram/g gel (indeholder 235 mikrogram ingenolmebutat) én gang om dagen 2 dage i træk.
500 micrograms/g gel (containing 235 micrograms of ingenol mebutate) once a day for 2 days in a row.
500 ml 1 l 2,5l
500 ml 1 l
500 ml flaske
500 ml bottle
500 ml flaske
BOTTLE LABEL
500 ml flaske af “high-density” polyethylen, lukket med gummiprop og forseglet med aluminiumskapsel.
500 ml of vaccine in high-density polyethylene bottles, closed with a nitrile rubber stopper and aluminium cap.
500 ml flaske indeholdende 490 ml oral opløsning / 1000 ml flaske indeholdende 980 ml oral opløsning.
500 ml bottle containing 490 ml of oral solution / 1000 ml bottle containing 980 ml of oral solution
500 ml flaske/1000 ml flaske
500 ml bottle/1000 ml bottle
500 ml opløsningsvæske
500 ml diluent
500 tabletter
500 tablets
500 til 1,000 mg engang daglig(2)
500 to 1,000 mg once daily (2)
500 µg
10 µg
500 µg
15 µg
500 µg
40 µg
500 µg i 1 ml
500 µg in 1 ml
500-1.000  µg/l
500-1,000 µg/l
500-1.000 µg
500-1,000 µg/l
500-1.000 µg/l
500-1,000 µg/l
500-749 celler/mm3: Uge 1-2 – afbryd dosering indtil >750 celler/mm3, fortsæt derefter dosering med 1. niveau justering, vurder ugentligt i de næste 3 uger for at bekræfte absolut neutrofilocyttal>750 celler/mm3; Uge 3-48 – øjeblikkelig 1. niveau justering.
500-749 cells/mm3: Week 1-2 - interrupt dosing until >750 cells/mm3 then resume dose with a 1 level adjustment, assess weekly for the next 3 weeks to verify ANC >750 cells/mm3; Week 3-48 - immediate 1 level adjustment.
500-749 celler/mm3: Uge 1-2 – afbryd dosering indtil >750 celler/mm3, fortsæt derefterdosering med 1. niveau justering, vurder ugentligt ide næste 3 uger for at bekræfte absolut neutrofilocyttal>750 celler/mm3; Uge 3-48 –øjeblikkelig 1. niveau justering.
500-749 cells/mm3: Week 1-2 - interrupt dosing until >750 cells/mm3 then resume dose with a 1 level adjustment, assess weekly for the next 3 weeks to verify ANC >750 cells/mm3; Week 3-48 - immediate 1 level adjustment.
500/125 mg to gange daglig ved
be increased to 500/125 mg twice
500/200 mg to gange
500/200 mg twice daily
5000 carbamoyl)-1,2-dipalmitoyl-sn-glycero-3-phosphatidylethanolamin, mononatriumsalt (MPEG5000 DPPE), natriumdihydrogenphosphat monohydrat, dinatrium hydrogenphosphatheptahydrat, natriumchlorid, propylenglycol, glycerol, vand til injektionsvæsker
1,2-dipalmitoyl-sn-glycero-3-phosphatidic acid, monosodium salt (DPPA), N-(methoxypolyethylene glycol 5000 carbamoyl)-1,2-dipalmitoyl-sn-glycero-3-phosphatidylethanolamine, monosodium salt (MPEG5000 DPPE), sodium dihydrogen phosphate monohydrate, disodium hydrogen phosphate heptahydrate, sodium chloride, propylene glycol, glycerol, water for injections
5000 doser
5,000 doses
5000 E/ml
5000 U/ml
50019 Sesto Fiorentino (FI) Italien
50019 Sesto Fiorentino (FI) Italy.
500ml 1 flaske 0 dage
Zero days
509 patienter med fremskreden brystcancer, som ikke tidligere havde modtaget kemoterapi for metastaserende sygdom, blev behandlet med Caelyx (n=254) i en dosis på 50 mg/m2 hver 4. uge, eller doxorubicin (n=255) i en dosis på 60 mg/m2 hver 3. uge, i en fase III klinisk undersøgelse (I97-328).
509 patients with advanced breast cancer who had not received prior chemotherapy for metastatic disease were treated with Caelyx (n=254) at a dose of 50 mg/m2 every 4 weeks, or doxorubicin (n=255) at a dose of 60 mg/m2 every 3 weeks, in a phase III clinical trial (I97-328).
50g 100g
5 mg/pump
50x1 filmovertrukne tabletter
50x1 film-coated tablets
50x1 tabletter i perforerede en-dosis PVC/PVDC/aluminum blister eller ren aluminium blister.
50x1 tablets in PVC/PVDC/Aluminium blisters or in all aluminium perforated unit-dose blisters.
50×1 kapsel
50×1 capsule
50–60 3,5 mg* zoledronsyre
50–60 3.5 mg* zoledronic acid
50–60 kg
50 – 60 kg
51 (39; 63)
OBT (N = 237)
51,5 til 53,3
51.5 to 53.3
51,9 %
NA
51-60 kg
51 – 60
51063 Köln Tyskland
51063 Cologne Germany
51368 Leverkusen Tyskland
51368 Leverkusen Germany
51377 Leverkusen, Tyskland
51377 Leverkusen, Germany
52 % af patienterne i AEGIS 1 og 33 % i AEGIS 2 havde haft en eksacerbation af sygdommen i de foregående seks måneder.
52 % of the patients in AEGIS 1 and 33 % in AEGIS 2 had a disease flare in the previous 6 months.
52 % og 39 %, og Cmax for levonorgestrel sænkedes med henholdsvis 46 % og 20 %, og median tmax blev forsinket med 1 til 3 timer.
39% respectively and Cmax of levonorgestrel was decreased by 46% and 20%, respectively and median tmax was delayed by 1 to 3 hours.
52 enheder
counter stopped: 52 units
52 enheder
Dose counter stopped: 52 units
52 tabletter
52 tablets
52 tabletter (13 blisterkort med 4 tabletter i hver) Ikke alle pakningsstørrelser er nødvendigvis markedsført.
52 tablets (13 blister strips with 4 tablets each) Not all pack sizes may be marketed.
52 uger
26 weeks
52 ugers monoterapi med liraglutid resulterede i statistisk signifikante og vedvarende reduktioner i HbA1c sammenlignet med glimepirid 8 mg (-0,84% for 1,2 mg, -1,14% for 1,8 mg versus -0,51% for komparator), hos patienter som tidligere blev behandlet med enten kost og motion eller monoterapi med orale antidiabetika, hvor dosis ikke var mere end halvdelen af den maksimale dosis (Tabel 2).
Liraglutide monotherapy for 52 weeks resulted in statistically significant and sustained reductions in HbA1c compared with glimepiride 8 mg (­0.84% for 1.2 mg, ­1.14% for 1.8 mg vs ­0.51% for comparator) in patients previously treated with either diet and exercise or OAD monotherapy at no more than half­maximal dose (Table 2).
52% af patienterne med virologisk svigt i rilpivirin-armen udviklede samtidig NNRTI- og NRTI-mutationer.
52% of patients with virologic failure in the rilpivirine arm developed concomitant NNRTI and NRTI mutations.
52% bevarede milt-respons i mindst 48 uger i COMFORT-II.
48 weeks in COMFORT-II.
52, Rue Marcel et Jacques Gaucher, 94120 Fontenay-sous-Bois, Frankrig
52, Rue Marcel et Jacques Gaucher, 94120 Fontenay-sous-Bois, France
52,4 % (24,6, 70,5)d
52.4% (24.6, 70.5)d
52,4% (24,6; 70,5)d
52.4% (24.6, 70.5)d
52,7 til 56,3
52.7 to 56.3
52,8; 72,3
LVL (≤600,000
52-54 Gracechurch Street London EC3V 0EH Storbritannien
52-54 Gracechurch Street London EC3V 0EH United Kingdom
52-54 Gracechurch Street London EC3V 0EH Storbritannien.
52-54 Gracechurch Street London EC3V 0EH United Kingdom
5216 PD ’s-Hertogenbosch The Netherlands
LT-08234 Vilnius, Lithuania
523 patienter med kæmpecelletumorer i knogle i enkeltarmede kliniske studier, der undersøgte XGEVAs virkning og sikkerhed.
523 patients with giant cell tumour of bone in single-arm, clinical trials examining the efficacy and safety of XGEVA.
525 mg (6,6 ml) to gange daglig
525 mg (6.6 ml) twice daily
53 pædiatriske patienter i alderen 2 til <18 år blev behandlet med voriconazol i to kliniske prospektive, åbne, ikke-komparative, multicenterstudier.
Fifty-three paediatric patients aged 2 to <18 years were treated with voriconazole in two prospective, open- label, non-comparative, multi-center clinical trials.
53,4 til 55,2
53.4 to 55.2
53,7 %; data har dog vist, at størstedelen af de nyfødte havde normal fødselsvægt for deres gestationelle alder) samt for hyperkaliæmi hos den nyfødte (forekomst hos 8 ud af 111 nyfødte, dvs.
53.7%; however, data showed that the majority of the newborns had normal birth weight for their gestational age) as well as for hyperkalaemia in the newborn (incidence 8 of 111 neonates, i.e.
53,7 %; dog viste data, at størstedelen af de nyfødte havde normal fødselsvægt for deres gestationsalder) såvel som hyperkaliæmi hos den nyfødte (forekomst hos 8 ud af 111 nyfødte, dvs.
53.7%; however, data showed that the majority of the newborns had normal birth weight for their gestational age) as well as for hyperkalaemia in the newborn (incidence 8 of 111 neonates, i.e.
53,7 (9,1 til -)
53.7 (9.1 to -)
53,9% og 19,4% (difference = 34,5%; 95% CI: 27,0%-42,0%) og CA uge 9-24 var 35,2% (vareniclin) vs.
27.0% - 42.0%) and the CA week 9-24 was 35.2% (varenicline) vs.
53018 Rosia Sovicille (SI) Italien.
53018 Rosia Sovicille (SI) Italy.
53018 Sovicille (Siena) Italien
53018 Sovicille (Siena) Italy.
53100 Siena Italien.
53100 Siena Italy.
53119 Bonn Tyskland
53119 Bonn Germany
532 g granulat + 3 doseringsskeer
532 g + 3 dosing spoons
53773 Hennef Tyskland
53773 Hennef Germany
54 IE/kg)
Success rate
54 patienter (herunder 2 patienter med lamivudinresistente mutationer ved baseline) fik indledningsvist blindet placebobehandling i 72 uger, og 52/54 patienter fik derefter tenofovirdisoproxilfumarat (PLB-TDF-gruppen).
Fifty-four patients (including 2 patients with lamivudine resistance mutations at baseline) initially received blinded placebo treatment for 72 weeks, and 52/54 patients followed with tenofovir disoproxil fumarate (PLB-TDF group).
54 patienter blev randomiseret til behandling med 2.500 E/m2 Oncaspar, og 111 patienter blev randomiseret til et andet pegyleret asparaginasepræparat.
of 166 patients were enrolled in this study; 54 patients were randomized to treatment with 2500 U/m2 Oncaspar and 111 patients were randomized to another pegylated asparaginase product.
54%; p < 0,0001
54%; P < .0001
54, rue La Boétie - F-75008 Paris - Frankrig
54, rue La Boétie - F-75008 Paris - France
54, rue La Boétie - F-75008 Paris - Frankrig
54, rue La Boétie F-75008 Paris France
54, rue La Boétie F – 75008 Paris Frankrig
54, rue La Boétie F – 75008 Paris France
54, rue La Boétie F-75008 Paris Frankrig
54, rue La Boétie F-75008 Paris France
54, rue La Boétie – F-75008 Paris Frankrig
54, rue La Boétie – F-75008 Paris France
54,2 ml/time) og 13,6 dage (i intervallet 2,4-36,0 dage) efter den ottende infusion og 12,1 ml/time (i intervallet 3,0-233 ml/time) og 11,5 dage (i intervallet 1,8-36,4 dage) efter den tolvte infusion.
8.5 ml/h (range 1.3-41.5 ml/h) and 11.5 days (range 2.3-30.6 days) after the fourth infusion, 11.7 ml/h (range 3.9-54.2 ml/h) and 13.6 days (range 2.4-36.0 days) after the eighth infusion, and 12.1 ml/h (range 3.0-233 ml/h) and 11.5 days (range 1.8-36.4 days) after the twelfth infusion.
54,3% af de patienter, der blev behandlet med Xultophy, nåede målet på HbA1c <7% uden bekræftede hypoglykæmiske episoder, sammenlignet med 29,4% af de patienter, der blev behandlet med insulin glargin (oddsratio 3,24; p < 0,001).
54.3% of patients treated with Xultophy reached the HbA1c target of <7% without confirmed hypoglycaemic episodes compared to 29.4% of patients treated with insulin glargine (odds ratio 3.24, p<0.001).
54500 Vandoeuvre les Nancy Frankrig
54500 Vandoeuvre les Nancy France
55 % af dosis blev udskilt som uomdannet migalastat, 4 % som M1, M2 og M3, og 5 % som ubestemte komponenter, i alt 64 %.
55% of the dose was excreted as unchanged migalastat, 4% as M1 to M3, and 5% was from unassigned components, for a total of 64%.
55 % af patienterne fik rhDNase i undersøgelse DPM-CF-301, mens dette tal var 75 % i undersøgelse DPM-CF-302.
Fifty five % of patients were receiving rhDNase in study DPM-CF-301 while in study DPM-CF-302 this number was 75%.
55 % af patienterne med ukendt EGFR-ekspressionsstatus var hazard ratio 0,77 (95 % konfidensinterval 0,61-0,98).
EGFR-expression status, the hazard ratio was 0.77 (95% CI 0.61-0.98).
55 % placebo efter 52 uger.
55% Placebo at 52Weeks.
55 mikrogram /
55 micrograms /
55 ml:  10 kg legemsvægt
55 ml:  10 kg BW
55% af de patienter, som blev behandlet med Levemir, fuldførte de 52 ugers behandling med et behandlingsregime på to gange daglig.
52 weeks of treatment on the twice daily regimen.
55%; p < 0,0001
55%; P < .0001
55, 120 eller 210 ml ravfarvet glasflaske (type III) med børnesikret polypropylenlukning og doseringspipette.
55, 120 or 210 ml amber glass bottle (type III) with a child resistant polypropylene closure and dosing pipette.
55,3 til 57,0
55.3 to 57.0
55,6 % (p = 0,021)*
55.6 % (p=0.021)
55,6 % (p = 0,021)*
55.6% (p=0.021)
55,6% (p = 0,021)*
55.6% (p=0.021)
55216 Ingelheim Tyskland
55216 Ingelheim am Rhein Germany
55216 Ingelheim TYSKLAND
55216 Ingelheim GERMANY
55216 Ingelheim/ Rhein Tyskland
55216 Ingelheim/Rhein GERMANY
5531 AE Bladel, Nederlandene
5531 AE Bladel,
5531 AE Bladel, Nederlandene
5531 AE Bladel, The Netherlands
56 % i siltuximabgruppen).
56% in the siltuximab group).
56 (2 x 28) tabletter (multipakning)
56 (2 x 28) tablets (multipack)
56 (4 blisterkort á 14)
56 (4 blisters of 14)
56 (53 %)a
56 (53%)a
56 af 84 patienter (67 %), der fik sebelipase alfa i de kliniske studier (LAL-CL01/LAL-CL04, LAL- CL02 og LAL-CL03), var børn og unge (1 måned op til 18 år).
Fifty-six of 84 patients (67%) who received sebelipase alfa during clinical studies (LAL-CL01/LAL- CL04, LAL-CL02 and LAL-CL03) were in the paediatric and adolescent age range (1 month up to 18 years).
56 ampuller x 1 administrations- anordning
56 ampoules x 1 administration device
56 dage efter inaktiveret vaccinea
56 Days after inactivated vaccinea
56 depottabletter
56 prolonged-release tablets
56 filmovertrukne tabletter (2 pakninger med 28 tabletter i hver).
56 film-coated tablets (2 packs of 28 tablets).
56 filmovertrukne tabletter 28 filmovertrukne tabletter 98 filmovertrukne tabletter 112 filmovertrukne tabletter
56 film-coated tablets 28 film-coated tablets 98 film-coated tablets 112 film-coated tablets
56 filmovertrukne tabletter 70x1 filmovertrukne tabletter 84 filmovertrukne tabletter
56 film-coated tablets 70x1 film coated-tablets 84 film-coated tablets
56 filmovertrukne tabletter.
56 film-coated tablets
56 hårde kapsler og én Turbospin-inhalator, hvilket er nok til 4 ugers brug.
56 hard capsules and one Turbospin powder inhaler device sufficient for 4 weeks use.
56 inhalationspulver i kapsler og 1 inhalator (ugepakning)
56 inhalation powder, hard capsules and 1 inhaler (weekly pack)
56 kapsler (4 blisterkort med 7 x 20 mg og 7 x 80 mg) (100 mg/dag dosis som forsyning til 28 dage)
56 capsules (4 blister cards of 7 x 20 mg and 7 x 80 mg) (100 mg/day dose for a 28 day supply)
56 kapsler (4 blisterkort med 7 x 20 mg og 7 x 80 mg) (100 mg/dag dosis)
56 capsules (4 blister cards of 7 x 20 mg and 7 x 80 mg) (100 mg/day dose)
56 kapsler med 1 Turbospin-inhalator (4 blisterstrips med 14 kapsler) 56 kapsler med 1 Turbospin-inhalator (7 blisterstrips med 8 kapsler)
56 capsules with 1 Turbospin inhaler (4 strips of 14 capsules) 56 capsules with 1 Turbospin inhaler (7 strips of 8 capsules)
56 Marsh Wall London E14 9TP England
56 Marsh Wall London E14 9TP United Kingdom
56 orodispergible tabletter
56 orodispersible tablets
56 overtrukne tabletter
56 coated tablets
56 pædiatriske patienter med PKU <4 år blev randomiseret i forholdet 1:1 til at få enten 10 mg/kg/dag Kuvan plus en fenylalaninbegrænset diæt (n=27) eller en fenylalaninbegrænset diæt alene (n=29) i løbet af en 26-ugers studieperiode.
56 paediatric PKU patients <4 years of age were randomized 1:1 to receive either 10 mg/kg/day Kuvan plus a phenylalanine-restricted diet (n=27), or just a phenylalanine-restricted diet (n=29) over a 26-week Study Period.
56 smeltetabletter
56 orodispersible tablets
56 tabletten
56 tablets
56 tabletter
(unit dose) 56 tablets
56 tabletter
EU/1/06/360/002
56 tabletter
EU/1/06/360/004 EU/1/06/360/005
56 tabletter
EU/1/12/755/014 [56 tablets]
56 tabletter
EU/1/12/755/023 [56 tablets]
56 tabletter
EU/1/12/756/014 [56 tablets]
56 tabletter
EU/1/12/765/012
56 tabletter (multipakni ng)
56 tablets (multipack)
56 tabletter (PA/Alu/PVC blister)
56 tablets (PA/Alu/PVC blisters)
56 tabletter (PVC/PCTFE blister)
56 tablets (PVC/PCTFE blisters)
56 tabletter (PVC/PCTFE enkeltdosisblister)
56 tablets (PVC/PCTFE single-unit-dose blisters)
56 tabletter 56x1 tabletter 90 tabletter
56 tablets 56x1 tablet 90 tablets
56 tabletter: EU/1/08/480/003
56 tablets: EU/1/08/480/003
56 tabletter: EU/1/10/632/004
56 tablets: EU/1/10/632/004
56 tabletter: EU/1/10/632/011
56 tablets: EU/1/10/632/011
56 tabletter: EU/1/10/632/018
56 tablets: EU/1/10/632/018
56 tabletter: EU/1/11/721/004
56 tablets: EU/1/11/721/004
56 tabletter: EU/1/11/721/011
56 tablets: EU/1/11/721/011
56 tabletter: EU/1/11/721/018
56 tablets: EU/1/11/721/018
56 tabletter: EU/1/11/723/004
56 tablets: EU/1/11/723/004
56 tabletter: EU/1/11/723/011
56 tablets: EU/1/11/723/011
56 tabletter: EU/1/11/723/018
56 tablets: EU/1/11/723/018
56 x 1
56
56 x 1 filmovertrukken tablet
56 x 1 film-coated tablets
56 x 1 filmovertrukken tablet
56 x1 film-coated tablet
56 x 1 filmovertrukket tablet
56 x 1 film-coated tablet
56 x 1 filmovertrukket tablet
56 x 1 film-coated tablets
56 x 1 filmovertrukne tabletter
56 x 1 film-coated tablets
56 x 1 filmovertrukne tabletter.
56 x 1 film-coated tablets
56 x 1 hårde kapsler
56 x 1 hard capsules
56 x 1 kapsler
56 x 1 capsules (unit
56 x 1 kapsler (enkeltdosis)
56 x 1 capsules (unit
56 x 1 kapsler (enkeltdosis)
56 x 1 capsules (unit dose)
56 x 1 smeltetablet
56 x 1 orodispersible tablet
56 x 1 smeltetablet: EU/1/09/525/029
56 x 1 orodispersible tablet:EU/1/09/525/029
56 x 1 smeltetablet: EU/1/09/525/034
56 x 1 orodispersible tablet:EU/1/09/525/034
56 x 1 smeltetablet: EU/1/09/525/039
56 x 1 orodispersible tablet:EU/1/09/525/039
56 x 1 smeltetablet: EU/1/09/525/044
56 x 1 orodispersible tablet:EU/1/09/525/044
56 x 1 tablet
56 x 1 tablets (unit dose)
56 x 1 tablet
56 x1 tablet
56 x 1 tablet (enhedsdosis)
56 x 1 tablet (unit dose)
56 x 1 tablet (enhedsdosis)
56 x 1 tablets (unit dose)
56 x 1 tablet (enkeltdosis)
56 x 1 tablet (unit dose)
56 x 1 tablet (enkeltstyk)
56 x 1 tablet (unit dose)
56 x 1 tableter (enkeltdosis)
56 x 1 tablets (unit dose)
56 x 1 tabletter
56 x 1 tablets
56 x 1 tabletter
56 x 1 tablets (unit
56 x 1 tabletter (enhedsdosis)
56 x 1 tablets (unit dose)
56 x 1 tabletter (enhedsdosis)
56x1 tablets (unit dose)
56 x 1 tabletter (enkeltdosis)
56 x 1 tablets (unit dose)
56 x 1 tabletter: EU/1/08/480/004
56 x 1 tablets: EU/1/08/480/004
56 x 1 tabletter: EU/1/08/480/010
56 x 1 tablets: EU/1/08/480/010
56 x 1 tabletter: EU/1/08/480/016
56 x 1 tablets: EU/1/08/480/016
56 x 1, 70, 70 x 1, 98 eller 98 x 1 filmovertrukne tabletter pr. karton.
70 x 1, 98 or 98 x 1 film-coated tablets per carton.
56 x1 filmovertrukne tablet
56 x 1 film-coated tablet
56%, p = 0,002) for patienter behandlet med det terapeutiske Zevalin-regimen.
56%, p = 0.002) for patients treated with the Zevalin therapeutic regimen.
56, 56 x 1, 60, 70, 70 x 1, 98 eller 98 x 1 filmovertrukne tabletter.
1, 56, 56 x 1, 60, 70, 70 x 1, 98 or 98 x 1 film-coated tablets.
56, 70 (2 x 35) og 70 filmovertrukne tabletter.
35, 56, 70 (2 x 35 multipack) and 70 film-coated tablets.
56, Marsh Wall London E14 9TP, Storbritannien
London E14 9TP United Kingdom
56,4 mdr. (52,8; 60,9)
56.4 mo (52.8, 60.9)
56,4 til 59,9
56.4 to 59.9
56,6 % på levetiracetam og 58,5 % på carbamazepin CR).
58.5 % of subjects on levetiracetam and on carbamazepine CR respectively).
56,6 (48,7 til o 68,4)
56.6 (48.7 to 68.4)
56,6b
24.7b
56,8 % (96/169) (p < 0,001)*
56.8% (96/169) (p<0.001)
56,8 % (96/169) (p < 0,001)*
56.8% (96/169) (p=0.001)
5600 IE
5600 IU
56x1 filmovertrukne tabletter (enhedsdosis) 98x1 filmovertrukne tabletter (enhedsdosis) 280x1 filmovertrukne tabletter (enhedsdosis)
56x1 film-coated tablet (unit dose) 98x1 film-coated tablet (unit dose) 280x1 film-coated tablet (unit dose)
56x1 hårde kapsler 84x1 hårde kapsler 112x1 hårde kapsler 140x1 hårde kapsler 168x1 hårde kapsler 56 hårde kapsler
56x1 hard capsules 84x1 hard capsules 112x1 hard capsules 140x1 hard capsules
56x1 kapsler (Enkeltdosisblister)
56x1 capsules (unit dose)
56x1 tabletter
56x1 tablets
56x1 tabletter (enkeltdosis)
56x1 tablet (unit dose)
56x1 tabletter (PVC/PCTFE enkeltdosisblister)
56x1 tablet (PVC/PCTFE single-unit-dose blisters)
57 %
Negative
57 % (208/368) af forsøgspersonerne i Victrelis-RGT-armen og 56 % (204/366) af forsøgspersonerne i Victrelis-PR48-armen havde ikke-detekterbart hcv-RNA i behandlingsuge 8 sammenlignet med 17 % (60/363) af forsøgspersonerne i PR-armen.
Fifty-seven percent (208/368) of subjects in the Victrelis-RGT arm and 56% (204/366) of subjects in the Victrelis-PR48 arm had undetectable HCV-RNA at TW 8 compared with 17% (60/363) of subjects in the PR arm.
57 % af det normale)
57% of normal)
57 % af patienterne i dette studie havde en HbA1c-baseline over 9%; disse patienter havde, efter behandling med NovoMix 30 kombineret med metformin, en HbA1c, som var betydelig lavere end de patienter, som var blevet behandlet med metformin og sulfonylurea.
In this trial, 57% of the patients had baseline HbA1c above 9%; in these patients, treatment with NovoMix 30 in combination with metformin resulted in significantly lower HbA1c than metformin in combination with sulfonylurea.
57 mg/g
57 mg
57,6 (483/838)
IGlar
57,8b
57.8b
570 patienter blev behandlet med Bosulif i dette studie, herunder patienter med CP CML, der tidligere var blevet behandlet med kun en TKI (imatinib), patienter med CP CML, der tidligere var blevet behandlet med imatinib og mindst en yderligere TKI (dasatinib og/eller nilotinib), patienter med AP eller BP CML, som tidligere var blevet behandlet med mindst en TKI (imatinib), og patienter med Ph+ ALL, der tidligere var blevet behandlet med mindst en TKI (imatinib).
There were 570 patients treated with Bosulif in this trial including CP CML patients previously treated with only one prior TKI (imatinib), CP CML patients previously treated with imatinib and at least 1 additional TKI (dasatinib and/or nilotinib), CML patients in accelerated or blast phase previously treated with at least one TKI (imatinib) and patients with Ph+ ALL previously treated with at least one TKI (imatinib).
58 a
58a
58 IE/kg)
32 IU/kg (22;
58 IE/kg)
58 IU/kg)
58,1 (45,6 til 82,1)
58.1 (45.6 to 82.1)
58,5 %
NA
58,8 mikrogram
58.8 micrograms
58-500 Jelenia Góra, Polen
58-500 Jelenia Góra, Poland
58/223 (26,0 %)a
58/223 (26.0%) a
58/223 (26,0 %)a
58/223 (26.0%)a
5831 AN Boxmeer Holland
5831 AN Boxmeer The Netherlands
5831AN Boxmeer Holland
5831AN Boxmeer The Netherlands
585 L/time efter intravenøs hvoraf den renale clearance er på 22 %.
The total clearance (mean ±SD) is approximately 58±5 l/h after an intravenous administration with renal clearance accounting for about 22% of this.
590 patienter med type 2 diabetes, mikroalbuminuri (30-300 mg/dag) og normal nyrefunktion (serum- kreatinin ≤ 1,5 mg/dl hos mænd og < 1,1 mg/dl hos kvinder).
IRMA 2 was a placebo-controlled double blind morbidity study in 590 patients with type 2 diabetes, microalbuminuria (30-300 mg/day) and normal renal function (serum creatinine ≤ 1.5 mg/dl in males and < 1.1 mg/dl in females).
590 patienter med type 2-diabetes, mikroalbuminuri (30-300 mg/dag) og normal nyrefunktion (serum- kreatinin ≤ 1,5 mg/dl hos mænd og < 1,1 mg/dl hos kvinder).
IRMA 2 was a placebo-controlled double blind morbidity study in 590 patients with type 2 diabetes, microalbuminuria (30-300 mg/day) and normal renal function (serum creatinine ≤ 1.5 mg/dl in males and < 1.1 mg/dl in females).
5928 LC Venlo Holland
5928 LC Venlo The Netherlands
59320 Ennigerloh Nordrhein-Westfalen
59320 Ennigerloh
59390 Lys-Lez-Lannoy Francia
59390 Lys-Lez-Lannoy France
5a Vend infusionsposen på hovedet og monter sprøjten på den blå port.
5a Invert the infusion bag and screw the syringe into Blue port.
5b Tøm indholdet af sprøjten i posen.
5b Empty the contents of the syringe into the bag.
5b) Påfør straks tilstrækkelig manuel kompression over hele EVARRESTs overflade (inklusive det overlappende område) til at sikre hæmostase, så at al blødning standses.
5b) To ensure haemostasis, immediately apply manual compression over the entire surface of the EVARREST (including the area of overlap) sufficient to stem all bleeding.
5Der blev rapporteret ødemer hos 6-9% af patienterne, der blev behandlet i et år med pioglitazon i kontrollerede kliniske studier.
5 Oedema was reported in 6–9% of patients treated with pioglitazone over one year in controlled clinical trials.
5Der blev udført en poolet analyse af bivirkninger i form af knoglefrakturer fra randomiserede, komparatorkontrollerede, dobbeltblindede kliniske forsøg med over 8.100 patienter i den pioglitazonbehandlede gruppe og 7.400 patienter i den komparatorbehandlede gruppe, der blev behandlet i op til 3,5 år.
5 A pooled analysis was conducted of adverse reactions of bone fractures from randomised, comparator controlled, double blind clinical trials in over 8100 patients in the pioglitazone-treated groups and 7400 in the comparator-treated groups of up to 3.5 years duration.